|
|
|
|
| Symbol(s): |
NKTR |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
Nektar Therapeutics has a current Overall Rating of C (Neutral). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| Nektar Therapeutics has a current Overall Rating of C (Neutral). Power Rating (86) is very high; appreciation potential (4) is negative. Relative to the S&P 500 Composite, Nektar Therapeutics has moderate Value characteristics -- its appeal is likely to be to Capital Gain-oriented investors. NKTR is of very low investment quality. Current annual total return performance of 11.2% is slightly below median. Current 5-year total return performance of -5.0% is lower quartile. Over the full...
| | |
|
|
